G-Pump

also known as glucagon

Developed for: hypoglycemia
Investigated by: Emissary International LLC · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Xeris Pharmaceuticals

Trials 1

today NCT02081001 · Ph 2

20142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT02081001	Mar → Aug 2014	hypoglycemia	Xeris Pharmaceuticals	Completed	Missed primary

News releases announcing trial results or a regulatory action · 4

Date	Issuer	Release
2018-12-20	Xeris Pharmaceuticals	Regulatory European Medicines Agency Grants Orphan Drug Designation for Xeris’ Investigational Ready-to-Use Glucagon for the Treatment of Non-Insulinoma Pancreatogenous Hypoglycaemia Syndrome (NIPHS) xerispharma.com ↗
2018-11-15	Xeris Pharmaceuticals	Results Xeris Pharmaceuticals Releases Additional Phase 3 Clinical Trial Data on Its Ready-to-Use Liquid Glucagon Pen xerispharma.com ↗ These data outline the glucagon pen’s efficacy in prompt and complete resolution of hypoglycemia in both adults and children with diabetes, as well as simplicity to facilitate successful administration during these critical settings.
2018-05-21	Xeris Pharmaceuticals	Results Xeris Pharmaceuticals Announces New Results From Ready-To-Use Liquid Glucagon Clinical Development Program xerispharma.com ↗ In a pilot study, patients with Type 1 diabetes (T1D) experienced normalization of plasma glucose levels and demonstrated complete resolution of symptoms of severe, experimentally induced hypoglycemia following a rescue dose of the company’s glucagon formulation.
2018-05-21	Xeris Pharmaceuticals	Regulatory DA Grants Orphan Drug Designation (ODD) for Xeris Pharmaceuticals' Ready-to-Use Glucagon for the Treatment of Hyperinsulinemic Hypoglycemia (HH). xerispharma.com ↗

All press releases naming this drug 23 releases

Date	Issuer	Release
2025-03-17	Xeris Pharmaceuticals	Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid xerispharma.com ↗
2021-04-29	Xeris Pharmaceuticals	Xeris Pharmaceuticals Receives U.K. MHRA Approval of Ogluo® (glucagon) Injection for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mellitus xerispharma.com ↗
2021-02-12	Xeris Pharmaceuticals	Xeris Pharmaceuticals Receives European Commission Approval of Ogluo™ (glucagon) Injection for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mellitus xerispharma.com ↗
2020-12-11	Xeris Pharmaceuticals	Xeris Pharmaceuticals Receives Positive CHMP Opinion for Ogluo™, Its Ready-To-Use (RTU) Glucagon for Injection, for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mellitus xerispharma.com ↗
2020-06-15	Xeris Pharmaceuticals	Xeris Pharmaceuticals Announces Positive Results From the Outpatient Stage of a Phase 2 Study of Its Developmental Gvoke Ready-to-Use (RTU) Micro™ Glucagon in Adults at Risk of Hypoglycemia During and After Aerobic Exercise xerispharma.com ↗
2020-05-22	Xeris Pharmaceuticals	Xeris Pharmaceuticals Announces Positive Findings From the Outpatient Portion of a Phase 2 Proof-of-Concept Study of Its Developmental Ready-to-Use (RTU) Glucagon in Patients at Risk of Postprandial Hypoglycemia Following Bariatric Surgery xerispharma.com ↗
2020-01-06	Xeris Pharmaceuticals	Xeris Pharmaceuticals Announces Positive Results from the In-Clinic Stage of a Phase 2 Study of Its Developmental Ready-To-Use (RTU) Glucagon in Patients at Risk of Hypoglycemia During and after Aerobic Exercise xerispharma.com ↗
2019-12-10	Xeris Pharmaceuticals	Xeris Pharmaceuticals Announces Positive Topline Results From the In-clinic Stage of the Phase 2 Study of Its Developmental Ready-to-use (RTU) Glucagon in Patients at Risk of Postprandial Hypoglycemia Following Bariatric Surgery xerispharma.com ↗
2019-09-10	Xeris Pharmaceuticals	Xeris Pharmaceuticals Receives U.S. FDA Approval for GVOKE™ (glucagon), the First Ready-to-use Stable Liquid Glucagon for Severe Hypoglycemia xerispharma.com ↗
2019-06-27	Xeris Pharmaceuticals	Xeris Pharmaceuticals Doses First Patient in Phase 2 Trial Evaluating Its Developmental Ready-to-use Glucagon in Patients at Risk From Hypoglycemia Following Bariatric Surgery xerispharma.com ↗
2019-06-17	Xeris Pharmaceuticals	Xeris Pharmaceuticals Announces Additional Positive Outcomes from a Global Phase 3 Clinical Trial of Its Investigational Ready-to-Use Glucagon xerispharma.com ↗
2019-03-25	Xeris Pharmaceuticals	Xeris Pharmaceuticals Presents New Clinical and Economic Impact Data on Its Developmental Ready-to-Use Glucagon xerispharma.com ↗
2019-03-14	Xeris Pharmaceuticals	Xeris Pharmaceuticals Doses First Patient in Phase 2 Trial Evaluating Its Ready-to-Use Glucagon to Address Exercise-Induced Hypoglycemia xerispharma.com ↗
2018-12-20	Xeris Pharmaceuticals	European Medicines Agency Grants Orphan Drug Designation for Xeris’ Investigational Ready-to-Use Glucagon for the Treatment of Non-Insulinoma Pancreatogenous Hypoglycaemia Syndrome (NIPHS) xerispharma.com ↗
2018-11-15	Xeris Pharmaceuticals	Xeris Pharmaceuticals Releases Additional Phase 3 Clinical Trial Data on Its Ready-to-Use Liquid Glucagon Pen xerispharma.com ↗
2018-10-23	Xeris Pharmaceuticals	Xeris Pharmaceuticals Announces FDA Acceptance for Review of NDA for Its Ready-to-Use Glucagon Rescue Pen xerispharma.com ↗
2018-08-17	Xeris Pharmaceuticals	Xeris Pharmaceuticals and OHSU Conducting Artificial Pancreas Clinical Trial Using Xeris’ Novel Ready-to-Use Liquid Glucagon xerispharma.com ↗
2018-06-25	Xeris Pharmaceuticals	Xeris Pharmaceuticals Announces Positive Phase 3 Clinical Trial Data on Its Investigational Ready-to-Use Glucagon Rescue Pen xerispharma.com ↗
2018-05-21	Xeris Pharmaceuticals	Xeris Pharmaceuticals’ Ready-to-Use Liquid Glucagon Clinical Data to Be Presented at American Diabetes Association 77th Scientific Sessions xerispharma.com ↗
2018-05-21	Xeris Pharmaceuticals	Xeris Pharmaceuticals Announces New Results From Ready-To-Use Liquid Glucagon Clinical Development Program xerispharma.com ↗
2018-05-21	Xeris Pharmaceuticals	DA Grants Orphan Drug Designation (ODD) for Xeris Pharmaceuticals' Ready-to-Use Glucagon for the Treatment of Hyperinsulinemic Hypoglycemia (HH). xerispharma.com ↗
2018-05-01	Xeris Pharmaceuticals	Xeris Pharmaceuticals Achieves Phase 3 Milestones of its Ready-to-Use Glucagon Rescue Pen for the Treatment of Severe Hypoglycemia xerispharma.com ↗
2018-05-01	Xeris Pharmaceuticals	Xeris Pharmaceuticals, Inc. Completes $55 million In New Financing To Support Ready-To-Use Glucagon Development xerispharma.com ↗

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	G-Pump	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02081001 ↗
Known as	glucagon	“The purpose of the study is to assess the safety, speed of absorption, and onset of action of G-Pump™ (glucagon infusion) at three subcutaneous doses as compared to Novo...” NCT02081001 ↗